Sinopharm Group CoSHTDF -2.67%78 EBITDA Margin % is 3.73% as of Dec. 2025, which is 21% below its 10-year median of 4.75. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 119 Medical Distribution companies, Sinopharm Group Co ranks worse than 57.98% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sinopharm Group Co's EBITDA for the
six
months ended in Dec. 2025 was $1,533 Mil. Sinopharm Group Co's Revenue for the
six
months ended in Dec. 2025 was $41,050 Mil. Therefore, Sinopharm Group Co's EBITDA margin for the quarter that ended in Dec. 2025 was 3.73%.
Sinopharm Group Co (OTCPK:SHTDF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sinopharm Group Co EBITDA Margin % Related Terms
Sinopharm Group Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTDF vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (SHTDF) has a EBITDA Margin % of 3.73% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinopharm Group Co and its competitors. This is 21% below median its historical median of 4.75. Over the past decade, Sinopharm Group Co's EBITDA Margin % has ranged from 3.67 to 4.96. According to the industry distribution chart, Sinopharm Group Co ranks #69 out of 119 companies in the Medical Distribution industry, placing it in the top 58%.
Is Sinopharm Group Co's EBITDA Margin % too high?
Sinopharm Group Co's current EBITDA Margin % of 3.73% is 21% below median its 10-year median of 4.75. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 4.96. The Medical Distribution industry median EBITDA Margin % is 4.31. Sinopharm Group Co's value of 3.73% is 13.5% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #69 out of 119 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #69 out of 119 companies for EBITDA Margin %. This places Sinopharm Group Co in the lower half of its industry. The industry median EBITDA Margin % is 4.31. Sinopharm Group Co's value of 3.73% is 13.5% below this benchmark. Historically, Sinopharm Group Co's own EBITDA Margin % has ranged from 3.67 to 4.96 over the past decade. While the company's 10-year median is 4.75 vs. the industry median of 4.31, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current EBITDA Margin % of 3.73% is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current EBITDA Margin % is 3.73%, which is 21% below median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current EBITDA Margin % is 3.73%, which is 21% below median its 10-year median of 4.75 and 13.5% below the Medical Distribution industry median of 4.31. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current EBITDA Margin % is 3.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
EBITDA Margin %: 3.73% (21% below median its 10-year median of 4.75)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 13.5% below the Medical Distribution median (#69 of 119)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
